KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $11.7 million.

  • Pacira BioSciences' Change in Accured Expenses fell 32.68% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 147.84%. This contributed to the annual value of $11.7 million for FY2024, which is 153.18% up from last year.
  • As of FY2024, Pacira BioSciences' Change in Accured Expenses stood at $11.7 million, which was up 153.18% from -$22.0 million recorded in FY2023.
  • Pacira BioSciences' Change in Accured Expenses' 5-year high stood at $11.7 million during FY2024, with a 5-year trough of -$22.0 million in FY2023.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$19.9 million (2022), whereas its average is -$10.1 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 190.87% in 2021, then plummeted by 464.28% in 2022.
  • Over the past 5 years, Pacira BioSciences' Change in Accured Expenses (Yearly) stood at -$6.0 million in 2020, then soared by 190.87% to $5.5 million in 2021, then slumped by 464.28% to -$19.9 million in 2022, then decreased by 10.99% to -$22.0 million in 2023, then soared by 153.18% to $11.7 million in 2024.